Approval · Notice of Compliance 28252 · 2022
NAT-BENDAMUSTINE: Notice of Compliance 28252
Issued May 24, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28252
- Date
- May 24, 2022
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph, To convert the product monograph to 2020 format, Update to the package insert, Update to labels
- Canadian reference product
- TREANDA (Teva Canada Limited)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-BENDAMUSTINE | Not yet assigned | — |
Medicinal ingredients
- BENDAMUSTINE HYDROCHLORIDE 25 MG per VIAL
- BENDAMUSTINE HYDROCHLORIDE 100 MG per VIAL